Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Expert Insights on Diabetes

Diabetes is a disease characterized by the body's inability to sufficiently produce insulin to properly metabolize carbohydrates. The three main forms the condition are Type 1, Type 2, and gestational diabetes. Type 1 diabetes is a chronic disease characterized by destruction of beta-cells of the pancreas. Type 2 diabetes develops when the body becomes resistant to the effects of insulin. Gestational diabetes is usually a temporary disorder occurring during pregnancy when insulin resistance develops due to hormonal changes and weight gain.

Gerson Lehrman Group Council Members are available to discuss Diabetes via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Michael Dempsey, Medical Director, Suburban Hospital.

Michael DempseyWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Medical DirectorSuburban Hospital.

Kelly Close, President, Close Concerns

Kelly CloseWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.What is a Premium Council Partner?|Premium Council Partners are leading Professional Service Firms that work exclusively with GLG.

PresidentClose Concerns

Satish Garg, MD, Professor of Medicine and Pediatrics , REGENTS OF THE UNIVERSITY OF COLORADO

Satish Garg, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Professor of Medicine and Pediatrics REGENTS OF THE UNIVERSITY OF COLORADO

George Griffing, MD, Director of General Internal Medicine, SAINT LOUIS UNIVERSITY

George Griffing, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Director of General Internal MedicineSAINT LOUIS UNIVERSITY

Ronald Innerfield, MD, Vice President of Clinical Affairs, Evidence Based Medicine, Inc.

Ronald Innerfield, MDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Vice President of Clinical AffairsEvidence Based Medicine, Inc.

Browse all 407 Leading Experts

Study Groups

Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry

Study Group Name No. Members
Byetta Prescribers for Diabetes 262
Byetta Prescribers for Diabetes (US) 227
Byetta Prescribers for Diabetes: Endocrinologists 150
Byetta Prescribers for Diabetes: Endocrinologists (US) 127
Diabetologists that Treat Type II Diabetes (US) 175

Browse all 974 Study Groups

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

Fresh Hope for Diabetes Patients

October 15, 2009

GLG Expert Contributor

ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com

The success of ONGLYZA (saxagliptin) will largely depend on its long-term safety. Saxagliptin is the second drug from this class to be approved in Europe and the US - Merck's Januvia (sitagliptin) was the first. Saxagliptin has had to overcome several new regulatory hurdles as a resultof...

Is the End of the Beginning of Diabetes Coming?

October 11, 2009

GLG Expert Contributor

Andromeda Biotech Consummates Deal with Teva for the Commercialization of DiaPep277, its Late Stage Development Drug for Type 1 Diabetes | www.pipelinereview.com

Teva's global operations and recognition in association with many generic drugs of different classes and for different indications across many speciaties will be immensely helpful in marketing DiaPep277 worldwide.

Diabetes Care Article Shows Sustained Benefits of CGM

September 18, 2009

Kelly Close, President, Close Concerns

Sustained Benefit of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes | care.diabetesjournals.org

A study by the JDRF CGM study group published in Diabetes Care showed sustained benefits of CGM use on A1c, glucose profiles, and rates of hypoglycemia in intensively managed adult type 1 diabetes patients. Patients spent significantly more time with glucose levels in the range of 71-180 mg/dl (3.9-10...

Amylin Partners with Biocon to Develop Novel Diabetes Therapeutic

September 15, 2009

Kelly Close, President, Close Concerns

Amylin and Biocon to partner on diabetes drug | www.forbes.com

Amylin Pharmaceuticals has entered into an agreement with Biocon to jointly develop, commercialize, and manufacture a novel anti-diabetes therapeutic. Amylin will contribute its peptide hormone development expertise, pursuing its renowned phybrid technology. Biocon will help manufacture the compound,...

Metagliptin too?

September 21, 2009

GLG Expert Contributor

Glenmark’s novel molecule for Diabetes, Melogliptin to enter phase III trials | www.pipelinereview.com

Yet another gliptin drug for diabetes is to start phse 3 trials.

Browse all 7647 GLG News Analyses

Contact Gerson Lehrman Group to engage a Diabetes expert